Möchten Sie immer auf dem neuesten Stand bleiben?

New York, April 08, 2026 (GLOBE NEWSWIRE) -- The Foundation for Opioid Response Efforts (FORE) has awarded a $473,675 grant to The Brookings Institution to develop new payment models that...

Strong participation in recent $33 million common stock offering highlights investor confidence in late-stage clinical momentum and commercial potential Statistical assessments point to high...

Issued claims further strengthen global intellectual property portfolio supporting immune cell modulation platform and expand strategic presence in a high-growth international market LA JOLLA, CA,...

First Interim Unblinding of Pivotal AML Trial Now Imminent — Potentially the Most Important Data Moment in Company HistoryEarly Blinded Results Show 40% Remission Rate Across Difficult-to-Treat...

Access the Moleculin CEO Corner here HOUSTON, March 11, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced it has released the next...

New Advisors Bring 50+ Years of Leadership Experience With 2 of the Top 10 Global Pharmaceuticals Companies Jericho, New York, March 11, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc....

SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- The disease of addiction has a domino effect – deeply impacting all relationships associated with the individual suffering in its grasp. The experts at...

All required regulatory approvals secured for trial site onboarding and patient enrollment at three Australian sitesPotential first and only pharmacological treatment for the most prominent...

CDI-988 is a direct-acting, oral antiviral being developed for norovirusNorovirus challenge study is underway at Emory University School of Medicine to evaluate efficacy and safety of CDI-988 No...

Toronto, Ontario, March 09, 2026 (GLOBE NEWSWIRE) -- The Entente Foundation (formerly RTOERO Foundation) has announced Dr. Jennifer Watt as the new Entente Education Canada Chair in Geriatric...